Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Biallelic loss-of-function variants in MGME1 underlie autosomal recessive mitochondrial DNA depletion syndrome 11. To date, two unrelated probands have been reported with homozygous frameshift and nonsense variants. The first individual harbored c.359del (p.Pro120LeufsTer2) presenting early-onset cerebellar ataxia, progressive external ophthalmoplegia, emaciation, respiratory failure, microcephaly, cerebellar atrophy, delayed speech and fundus albipunctatus (PMID:28711739). A second case carried c.862C>T (p.Gln288Ter) with chronic progressive external ophthalmoplegia, frequent falls, pes planus, diffuse hypotonia, cerebellar atrophy, mild respiratory involvement, and learning difficulty (PMID:37429773). No additional segregation data are available, yielding a Limited evidence level based on two unrelated probands and consistent clinical features.
Structural and biochemical studies have elucidated MGME1 as a mitochondria-specific DNase essential for correct mtDNA maintenance. High-resolution HsMGME1–DNA complex structures combined with in vitro cleavage assays define a two-cation catalytic mechanism underpinning directional DNA processing, congruent with loss-of-function pathogenicity (PMID:30247721). There are no reported conflicting data. Overall, current genetic and experimental findings support a Limited clinical validity for MGME1 in mitochondrial DNA depletion syndrome 11. Further cases and segregation analyses are needed. Key take-home: MGME1 should be included in diagnostic panels for early-onset cerebellar ataxia and mitochondrial depletion syndromes when biallelic truncating variants are identified.
Gene–Disease AssociationLimitedTwo unrelated probands with homozygous loss-of-function variants and consistent phenotype Genetic EvidenceLimitedTwo probands with biallelic truncating MGME1 variants Functional EvidenceModerateStructural and in vitro assays demonstrate MGME1’s DNase mechanism supporting loss-of-function pathogenicity |